Medicine and Health Sciences Commons^™

Expression Of Constitutively Active Raf-1 In The Mitochondria Restores Antiapoptotic And Leukemogenic Potential Of A Transformation-Deficient Bcr/Abl Mutant., P Salomoni, M A Wasik, R F Riedel, K Reiss, J K Choi, T Skorski, B Calabretta

Department of Microbiology and Immunology Faculty Papers

The oncogenic BCR/ABL protein protects hematopoietic cells from apoptosis induced by growth factor deprivation, but the mechanisms are only partially understood. A BCR/ABL mutant lacking amino acids 176-426 in the BCR domain (p185DeltaBCR) failed to protect interleukin 3-deprived 32Dcl3 myeloid precursor cells from apoptosis, although it possessed tyrosine kinase activity and was capable of activating the Ras-Raf-MAP kinase pathway. Compared to p185 wild-type transfectants, p185DeltaBCR-transfected cells showed markedly reduced levels of Bcl-2 and expressed the hypophosphorylated, proapoptotic form of BAD. Bcl-2 expression in the mitochondrial fraction of p185DeltaBCR cells was also markedly diminished and mitochondrial RAF was undetectable. In p185DeltaBCR …

Oncolog, Volume 43, Number 02, February 1998, Beth W. Allen, Alison Rufffin, Rebecca D. Pentz Ph.D.

OncoLog MD Anderson's Report to Physicians (All issues)

• Genetic findings prompt cancer survivor to elect surgery
• Protocols: Radiotherapy Protocols Offer Treatment for Range of Sites and Types of Cancer
• Radiation oncology: targeting effective treatment
• House Call: Cancer: Is it in the Genes or in the Stars?
• DiaLog: Genetic Tests Demand New Answers by Rebecca D. Pentz, PhD, Clinical Ethicist